Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exagen stock

Own Exagen stock in just a few minutes.

Exagen Inc is a diagnostics & research business based in the US. Exagen shares (XGN) are listed on the NASDAQ and all prices are listed in US Dollars. Exagen employs 181 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Exagen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Exagen share price

Use our graph to track the performance of XGN stocks over time.

Exagen shares at a glance

Information last updated 2021-04-23.
52-week range$10.29 - $23.18
50-day moving average $18.15
200-day moving average $16.07
Wall St. target price$26.60
PE ratio 0.3759
Dividend yield N/A (0%)
Earnings per share (TTM) $-293.37

Buy Exagen shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exagen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Exagen under- or over-valued?

Valuing Exagen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exagen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exagen's P/E ratio

Exagen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Exagen shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Exagen financials

Revenue TTM $42 million
Gross profit TTM $25.4 million
Return on assets TTM -11.24%
Return on equity TTM -34.23%
Profit margin -39.76%
Book value $4.67
Market capitalisation $263.7 million

TTM: trailing 12 months

Shorting Exagen shares

There are currently 94,558 Exagen shares held short by investors – that's known as Exagen's "short interest". This figure is 12.6% down from 108,218 last month.

There are a few different ways that this level of interest in shorting Exagen shares can be evaluated.

Exagen's "short interest ratio" (SIR)

Exagen's "short interest ratio" (SIR) is the quantity of Exagen shares currently shorted divided by the average quantity of Exagen shares traded daily (recently around 92703.921568627). Exagen's SIR currently stands at 1.02. In other words for every 100,000 Exagen shares traded daily on the market, roughly 1020 shares are currently held short.

However Exagen's short interest can also be evaluated against the total number of Exagen shares, or, against the total number of tradable Exagen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exagen's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Exagen shares in existence, roughly 10 shares are currently held short) or 0.0099% of the tradable shares (for every 100,000 tradable Exagen shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exagen.

Find out more about how you can short Exagen stock.

Exagen share dividends

We're not expecting Exagen to pay a dividend over the next 12 months.

Exagen overview

Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes designed to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site